(PFE) Pfizer - Overview

Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: NYSE (USA) | Market Cap: 146.248m USD | Total Return: 20.5% in 12m

Vaccines, Oncology Drugs, Biopharmaceuticals, Rare Disease Medicines
Total Rating 50
Safety 77
Buy Signal -0.35
Drug Manufacturers - General
Industry Rotation: +12.7
Market Cap: 146B
Avg Turnover: 970M
Risk 3d forecast
Volatility23.0%
VaR 5th Pctl3.93%
VaR vs Median3.74%
Reward TTM
Sharpe Ratio0.72
Rel. Str. IBD42.7
Rel. Str. Peer Group42.2
Character TTM
Beta0.439
Beta Downside0.515
Hurst Exponent0.430
Drawdowns 3y
Max DD40.75%
CAGR/Max DD-0.15
CAGR/Mean DD-0.25
EPS (Earnings per Share) EPS (Earnings per Share) of PFE over the last years for every Quarter: "2021-03": 0.93, "2021-06": 1.07, "2021-09": 1.34, "2021-12": 1.08, "2022-03": 1.62, "2022-06": 2.04, "2022-09": 1.78, "2022-12": 1.14, "2023-03": 1.23, "2023-06": 0.67, "2023-09": -0.17, "2023-12": 0.1, "2024-03": 0.82, "2024-06": 0.6, "2024-09": 1.06, "2024-12": 0.63, "2025-03": 0.92, "2025-06": 0.78, "2025-09": 0.87, "2025-12": 0.66, "2026-03": 0.75,
EPS CAGR: 10.46%
EPS Trend: 23.8%
Last SUE: 0.27
Qual. Beats: 0
Revenue Revenue of PFE over the last years for every Quarter: 2021-03: 14516, 2021-06: 18899, 2021-09: 24035, 2021-12: 23838, 2022-03: 25661, 2022-06: 27742, 2022-09: 22638, 2022-12: 24290, 2023-03: 18486, 2023-06: 12734, 2023-09: 13491, 2023-12: 14570, 2024-03: 14879, 2024-06: 13283, 2024-09: 17702, 2024-12: 17763, 2025-03: 13715, 2025-06: 14653, 2025-09: 16654, 2025-12: 17557, 2026-03: 14451,
Rev. CAGR: -2.41%
Rev. Trend: -24.4%
Last SUE: 0.70
Qual. Beats: 0

Warnings

Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: PFE Pfizer

Pfizer Inc. is a global biopharmaceutical company engaged in the research, development, and distribution of medicines and vaccines. The firm operates through three primary segments: Biopharma, PC1, and Pfizer Ignite. Its product portfolio spans internal medicine, oncology, immunology, and rare diseases, featuring established brands such as Eliquis, Prevnar, and Ibrance. Pfizer utilizes a diversified business model that combines internal R&D with strategic collaborations, such as its partnership with BioNTech for mRNA technology.

The pharmaceutical sector is characterized by high capital expenditures and long regulatory lead times, often requiring decades to bring a single molecule to market. Pfizer maintains a competitive position through its extensive pipeline of antibody-drug conjugates (ADCs) and small molecule therapies. The company has recently expanded its technological capabilities by integrating AI foundation models into its drug discovery process. For a deeper look at these fundamentals, you may find ValueRays detailed analysis useful.

Headquartered in New York and founded in 1849, Pfizer remains one of the largest patent-holding entities in the healthcare industry. Its revenue streams are globally diversified, supported by a mix of specialized oncology treatments and high-volume sterile injectables. The company continues to manage a broad range of biosimilars and anti-infective medicines across international markets.

Headlines to Watch Out For
  • Seagen acquisition integration determines long-term oncology revenue and margin expansion
  • COVID-19 product demand volatility impacts annual earnings and cash flow stability
  • Vyndaqel and Eliquis sales growth offsets upcoming patent expirations on legacy brands
  • New product launch execution across immunology and vaccines dictates mid-term valuation
  • Cost realignment initiatives and R&D efficiency targets influence operational profit margins
Piotroski VR‑10 (Strict) 5.0
Net Income: 7.49b TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.83 > 1.0
NWC/Revenue: 13.38% < 20% (prev 15.06%; Δ -1.68% < -1%)
CFO/TA 0.06 > 3% & CFO 11.98b > Net Income 7.49b
Net Debt (62.75b) to EBITDA (16.94b): 3.70 < 3
Current Ratio: 1.25 > 1.5 & < 3
Outstanding Shares: last quarter (5.73b) vs 12m ago 0.37% < -2%
Gross Margin: 69.35% > 18% (prev 0.67%; Δ 6.87k% > 0.5%)
Asset Turnover: 30.47% > 50% (prev 30.03%; Δ 0.44% > 0%)
Interest Coverage Ratio: 4.02 > 6 (EBITDA TTM 16.94b / Interest Expense TTM 2.69b)
Altman Z'' 3.45
A: 0.04 (Total Current Assets 42.82b - Total Current Liabilities 34.35b) / Total Assets 207.62b
B: 0.56 (Retained Earnings 117.24b / Total Assets 207.62b)
C: 0.05 (EBIT TTM 10.79b / Avg Total Assets 207.82b)
D: 0.94 (Book Value of Equity 110.52b / Total Liabilities 117.21b)
Altman-Z'' Score: 3.45 = A
Beneish M -3.19
DSRI: 0.84 (Receivables 12.59b/14.74b, Revenue 63.31b/62.46b)
GMI: 0.97 (GM 69.35% / 66.93%)
AQI: 1.01 (AQ_t 0.70 / AQ_t-1 0.69)
SGI: 1.01 (Revenue 63.31b / 62.46b)
TATA: -0.02 (NI 7.49b - CFO 11.98b) / TA 207.62b)
Beneish M-Score: -3.19 (Cap -4..+1) = AA
What is the price of PFE shares? As of May 22, 2026, the stock is trading at USD 25.95 with a total of 16,292,348 shares traded.
Over the past week, the price has changed by +0.78%, over one month by -3.41%, over three months by -2.52% and over the past year by +20.50%.
Is PFE a buy, sell or hold? Pfizer has received a consensus analysts rating of 3.56. Therefor, it is recommend to hold PFE.
  • StrongBuy: 7
  • Buy: 2
  • Hold: 15
  • Sell: 0
  • StrongSell: 1
What are the forecasts/targets for the PFE price?
Analysts Target Price 29.2 12.5%
Pfizer (PFE) - Fundamental Data Overview as of 21 May 2026
P/E Trailing = 19.5878
P/E Forward = 8.6281
P/S = 2.3098
P/B = 1.6023
P/EG = 13.7734
Revenue TTM = 63.31b USD
EBIT TTM = 10.79b USD
EBITDA TTM = 16.94b USD
Long Term Debt = 59.84b USD (from longTermDebt, last quarter)
Short Term Debt = 3.89b USD (from shortTermDebt, last quarter)
Debt = 64.45b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 62.75b USD (from netDebt column, last quarter)
Enterprise Value = 197.63b USD (146.25b + Debt 64.45b - CCE 13.07b)
Interest Coverage Ratio = 4.02 (Ebit TTM 10.79b / Interest Expense TTM 2.69b)
EV/FCF = 20.84x (Enterprise Value 197.63b / FCF TTM 9.48b)
FCF Yield = 4.80% (FCF TTM 9.48b / Enterprise Value 197.63b)
FCF Margin = 14.98% (FCF TTM 9.48b / Revenue TTM 63.31b)
Net Margin = 11.83% (Net Income TTM 7.49b / Revenue TTM 63.31b)
Gross Margin = 69.35% ((Revenue TTM 63.31b - Cost of Revenue TTM 19.41b) / Revenue TTM)
Gross Margin QoQ = 67.26% (prev 69.97%)
Tobins Q-Ratio = 0.95 (Enterprise Value 197.63b / Total Assets 207.62b)
Interest Expense / Debt = 1.04% (Interest Expense 668.0m / Debt 64.45b)
Taxrate = 14.54% (461.0m / 3.17b)
NOPAT = 9.22b (EBIT 10.79b * (1 - 14.54%))
Current Ratio = 1.25 (Total Current Assets 42.82b / Total Current Liabilities 34.35b)
Debt / Equity = 0.72 (Debt 64.45b / totalStockholderEquity, last quarter 90.10b)
Debt / EBITDA = 3.70 (Net Debt 62.75b / EBITDA 16.94b)
Debt / FCF = 6.62 (Net Debt 62.75b / FCF TTM 9.48b)
Total Stockholder Equity = 89.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.60% (Net Income 7.49b / Total Assets 207.62b)
RoE = 8.37% (Net Income TTM 7.49b / Total Stockholder Equity 89.52b)
RoCE = 7.22% (EBIT 10.79b / Capital Employed (Equity 89.52b + L.T.Debt 59.84b))
RoIC = 6.07% (NOPAT 9.22b / Invested Capital 151.88b)
WACC = 5.50% (E(146.25b)/V(210.70b) * Re(7.53%) + D(64.45b)/V(210.70b) * Rd(1.04%) * (1-Tc(0.15)))
Discount Rate = 7.53% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: 55.56 | Cagr: 0.66%
[DCF] Terminal Value 85.30% ; FCFF base≈10.18b ; Y1≈9.23b ; Y5≈8.05b
[DCF] Fair Price = 31.49 (EV 242.21b - Net Debt 62.75b = Equity 179.46b / Shares 5.70b; r=6.0% [WACC]; 5y FCF grow -11.59% → 3.0% )
EPS Correlation: 23.79 | EPS CAGR: 10.46% | SUE: 0.27 | # QB: 0
Revenue Correlation: -24.44 | Revenue CAGR: -2.41% | SUE: 0.70 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.68 | Chg30d=+0.24% | Revisions=-5% | Analysts=18
EPS next Quarter (2026-09-30): EPS=0.85 | Chg30d=-1.73% | Revisions=+10% | Analysts=18
EPS current Year (2026-12-31): EPS=2.96 | Chg30d=+0.00% | Revisions=+8% | GrowthEPS=-8.0% | GrowthRev=-1.4%
EPS next Year (2027-12-31): EPS=2.84 | Chg30d=+0.87% | Revisions=+17% | GrowthEPS=-4.2% | GrowthRev=-3.8%
[Analyst] Revisions Ratio: +17%